SG11202006712XA - Treatment of ophthalmologic diseases - Google Patents
Treatment of ophthalmologic diseasesInfo
- Publication number
- SG11202006712XA SG11202006712XA SG11202006712XA SG11202006712XA SG11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- ophthalmologic diseases
- ophthalmologic
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627103P | 2018-02-06 | 2018-02-06 | |
| US201862729333P | 2018-09-10 | 2018-09-10 | |
| PCT/EP2019/052704 WO2019154776A1 (en) | 2018-02-06 | 2019-02-05 | Treatment of ophthalmologic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006712XA true SG11202006712XA (en) | 2020-08-28 |
Family
ID=65352014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006712XA SG11202006712XA (en) | 2018-02-06 | 2019-02-05 | Treatment of ophthalmologic diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210139576A1 (en) |
| EP (1) | EP3749359A1 (en) |
| JP (3) | JP7005772B2 (en) |
| KR (2) | KR20240093772A (en) |
| CN (1) | CN111699004A (en) |
| AU (1) | AU2019219004A1 (en) |
| CA (1) | CA3088355A1 (en) |
| IL (1) | IL276383B2 (en) |
| MX (1) | MX2020007527A (en) |
| SG (1) | SG11202006712XA (en) |
| TW (2) | TWI831764B (en) |
| WO (1) | WO2019154776A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| IL290457B1 (en) | 2015-12-30 | 2024-10-01 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| WO2019147944A1 (en) | 2018-01-26 | 2019-08-01 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disordres using anti-vegf agents |
| JP2021514656A (en) | 2018-03-02 | 2021-06-17 | コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | IL-6 antibody and its fusion constructs and conjugates |
| AU2020326243A1 (en) * | 2019-08-06 | 2022-02-17 | F. Hoffmann-La Roche Ag | Personalized treatment of ophthalmologic diseases |
| EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| MX2022006241A (en) | 2019-11-25 | 2022-08-22 | Univ California | Long-acting vegf inhibitors for intraocular neovascularization. |
| CN116323663A (en) * | 2020-09-04 | 2023-06-23 | 豪夫迈·罗氏有限公司 | Antibodies that bind VEGF-A and ANG2 and methods of use thereof |
| WO2022057888A1 (en) * | 2020-09-17 | 2022-03-24 | 江苏恒瑞医药股份有限公司 | Bispecific antigen binding molecule specifically binding to vegf and ang-2 |
| US20240158489A1 (en) * | 2021-03-30 | 2024-05-16 | Abpro Corporation | Methods for treating choroidal neovascularization using anti-ang2 x vegf multi-specific antibodies |
| CN117100845A (en) * | 2022-10-24 | 2023-11-24 | 景泽生物医药(合肥)股份有限公司 | Application of recombinant human Octoplasmin in preparing medicine for treating choroidal vascular diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1787999B1 (en) | 1997-04-07 | 2010-08-04 | Genentech, Inc. | Anti-VEGF antibodies |
| WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| CN101198698B (en) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | Process for production of polypeptide by regulation of assembly |
| SI1999154T1 (en) | 2006-03-24 | 2013-01-31 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| EP3505636A1 (en) | 2009-04-27 | 2019-07-03 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| MX341796B (en) | 2009-12-29 | 2016-09-02 | Emergent Product Dev Seattle | Heterodimer binding proteins and uses thereof. |
| TWI426920B (en) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| US9562109B2 (en) | 2010-11-05 | 2017-02-07 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| SG191334A1 (en) * | 2011-01-13 | 2013-08-30 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| DK2794905T3 (en) | 2011-12-20 | 2020-07-06 | Medimmune Llc | MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY BASIC STRUCTURES |
| SI2838918T1 (en) | 2012-04-20 | 2019-11-29 | Merus Nv | Methods and means for the production of heterodimeric ig-like molecules |
| CN104428315B (en) * | 2012-07-13 | 2017-09-29 | 罗氏格黎卡特股份公司 | Bispecific anti-vegf/antibody of anti-ANG 2 and its application in treatment Ocular Vessels disease |
| RU2680096C2 (en) * | 2012-08-21 | 2019-02-15 | ОПКО ФАРМАСЬЮТИКАЛС, Эл Эл Си | Liposome formulations |
| PL2992010T3 (en) * | 2013-04-29 | 2021-08-23 | F.Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| KR20150063728A (en) | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | Anti-VEGF-C/anti-Ang2 bispecific antibody |
| TWI738632B (en) * | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | Stable protein solution formulation containing high concentration of an anti-vegf antibody |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| CN114306575A (en) * | 2014-12-11 | 2022-04-12 | 拜耳医药保健有限责任公司 | Treatment of age-related macular degeneration with small active choroidal neovascularisation |
| AR103477A1 (en) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | VEGFA / ANG2 COMPOUNDS |
| US10654922B2 (en) * | 2016-05-13 | 2020-05-19 | Askgene Pharma Inc. | Angiopoietin 2, VEGF dual antagonists |
| EP3472177B1 (en) * | 2016-06-17 | 2024-08-14 | F. Hoffmann-La Roche AG | Purification of multispecific antibodies |
-
2019
- 2019-02-05 JP JP2020536578A patent/JP7005772B2/en active Active
- 2019-02-05 MX MX2020007527A patent/MX2020007527A/en unknown
- 2019-02-05 SG SG11202006712XA patent/SG11202006712XA/en unknown
- 2019-02-05 WO PCT/EP2019/052704 patent/WO2019154776A1/en unknown
- 2019-02-05 KR KR1020247016479A patent/KR20240093772A/en unknown
- 2019-02-05 CA CA3088355A patent/CA3088355A1/en active Pending
- 2019-02-05 CN CN201980011416.4A patent/CN111699004A/en active Pending
- 2019-02-05 KR KR1020207025450A patent/KR20200119274A/en not_active IP Right Cessation
- 2019-02-05 AU AU2019219004A patent/AU2019219004A1/en active Pending
- 2019-02-05 EP EP19703978.7A patent/EP3749359A1/en active Pending
- 2019-02-05 IL IL276383A patent/IL276383B2/en unknown
- 2019-02-11 TW TW108104518A patent/TWI831764B/en active
- 2019-02-11 TW TW113103154A patent/TW202419464A/en unknown
-
2020
- 2020-08-05 US US16/985,477 patent/US20210139576A1/en not_active Abandoned
-
2022
- 2022-01-05 JP JP2022000341A patent/JP7273204B2/en active Active
-
2023
- 2023-02-09 US US18/166,996 patent/US20230416353A1/en active Pending
- 2023-04-27 JP JP2023073187A patent/JP2023099094A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020007527A (en) | 2020-09-09 |
| KR20200119274A (en) | 2020-10-19 |
| JP2023099094A (en) | 2023-07-11 |
| JP2021506947A (en) | 2021-02-22 |
| IL276383B1 (en) | 2023-09-01 |
| TWI831764B (en) | 2024-02-11 |
| JP2022046738A (en) | 2022-03-23 |
| WO2019154776A1 (en) | 2019-08-15 |
| IL276383B2 (en) | 2024-01-01 |
| CN111699004A (en) | 2020-09-22 |
| US20210139576A1 (en) | 2021-05-13 |
| JP7273204B2 (en) | 2023-05-12 |
| US20230416353A1 (en) | 2023-12-28 |
| EP3749359A1 (en) | 2020-12-16 |
| AU2019219004A1 (en) | 2020-07-16 |
| CA3088355A1 (en) | 2019-08-15 |
| TW202419464A (en) | 2024-05-16 |
| TW202000700A (en) | 2020-01-01 |
| IL276383A (en) | 2020-09-30 |
| KR20240093772A (en) | 2024-06-24 |
| JP7005772B2 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276383B1 (en) | Treatment of ophthalmologic diseases | |
| SG11202006374VA (en) | Treatment of demyelinating diseases | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| IL268357A (en) | Photoreceptor cells for the treatment of retinal diseases | |
| IL289405A (en) | Personalized treatment of ophthalmologic diseases | |
| IL282643A (en) | Combination therapy for treatment of hematological diseases | |
| SG11202010585WA (en) | New treatment of interstitial lung diseases | |
| SG11202001595SA (en) | Angio-3 for treatment of retinal angiogenic diseases | |
| SG11202007082PA (en) | Composition used for therapeutic treatment of skin disease | |
| ZA202002075B (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases | |
| IL269698B (en) | Methods of preventing or treating ophthalmic diseases | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| GB202015959D0 (en) | Treatment of diseases involving NAD | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| IL282361A (en) | Treatment of neurological diseases | |
| IL282898A (en) | Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases | |
| GB201914516D0 (en) | Treatment of eye disease | |
| EP3787749A4 (en) | Methods of treating retinal diseases | |
| SG11202010034WA (en) | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY | |
| GB201909438D0 (en) | Treatment of diseases | |
| GB201604359D0 (en) | Treatment of tissue disorders | |
| GB201805556D0 (en) | Treatment of ophthalmological conditions | |
| GB201904764D0 (en) | Treatment of ophthalmological conditions | |
| GB201811912D0 (en) | Treatment of disease | |
| GB201811911D0 (en) | Treatment of disease |